J&J will now explore Rybrevant's efficacy and safety in a Phase III trial in first-line, EGFR-driven HNSCC and colorectal ...

The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare ...

A&O Shearman and CMS have emerged as the top legal advisers in terms of deal value and deal volume, respectively.

Wachtell, Lipton, Rosen & Katz and Kirkland & Ellis have emerged as the top M&A legal advisers in North America in terms of ...

Goldman Sachs and UBS have secured their positions as the leading mergers and acquisitions (M&A) financial advisers in the ...

Paul Hastings and TriLegal have emerged as the leading mergers and acquisitions (M&A) legal advisers in the Asia-Pacific ...

Goldman Sachs and Houlihan Lokey have emerged as the leading mergers and acquisitions (M&A) financial advisers in North ...

Bank of America and Rothschild & Co have secured the leading positions as financial advisers in Europe's M&A sector.

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.